[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:acute-lymphoblastic-leukemia:cd22-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Acute Lymphoblastic Leukemia","CD22 Gene",6,[8,16,23,29,35,41],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04747912","Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",[12],"Phase 2","RECRUITING","2026-08-26T02:18:33.598205Z","2026-06-06T00:48:49.516454Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06408194","Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",[20],"Phase 1","2026-08-26T02:16:54.876240Z","2026-05-05T02:43:29.029325Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06777979","CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:26.924544Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":27,"content_modified":34},"NCT03104491","Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia",[33],"Phase 1\u002FPhase 2","2026-05-05T02:35:31.864785Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[20],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z",{"nct_id":42,"title":43,"phases":44,"status":45,"updated_at":46,"content_modified":47},"NCT03226704","Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:13.549512Z","2026-06-16T05:54:07.964568Z"]